Efficacy and safety of oxitropium bromide, theophylline and their combination in COPD patients: A double-blind, randomized, multicentre study (BREATH trial)

Respiratory Medicine

Volumn 96, Issue 11, 2002, Pages 881-889

  Bellia, V ^a   Foresi, A ^b   Bianco, S ^c   Grassi, V ^d   Olivieri, D ^e   Bensi, G ^f   Volonte M ^f  

^a Istituto Clinica Delle Malattie Apparato Respiration   (Italy)

^b Servizio di Pneumologia e Fisiopatologia Respiratoria   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e UNIVERSITY OF PARMA   (Italy)

^f Boehringer Ingelheim Italia SpA   (Italy)

Author keywords

COPD; Oxitropium bromide; Peak expiratory flow rate; Quality of life; Theophylline; Treatment

Indexed keywords

BRONCHODILATING AGENT; OXITROPIUM BROMIDE; PLACEBO; STEROID; THEOPHYLLINE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EPIGASTRIC PAIN; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL DISEASE; HEALTH STATUS; HUMAN; ITALY; LUNG CAPACITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; OUTPATIENT DEPARTMENT; PARALLEL DESIGN; PEAK EXPIRATORY FLOW; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN DISEASE; SPIROMETRY; STATISTICAL SIGNIFICANCE; SUSTAINED DRUG RELEASE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0036827958     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2002.1380     Document Type: Article

References (35)

1. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: S77-S121.
2. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997; 52 (Suppl 5): S1-S28.
3. Vaz Fragoso CA, Miller MA. Review of the clinical efficacy of theophylline in the treatment of chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 147: S40-S47.
4. Cazzola M, Centanni S, Donner CF. Anticholinergic agents. Pulm Pharmacol Ther 1998; 11: 381-392.
5. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Care Med 1997; 155: 1283-1289.
6. Clark CJ, Boyd G. Combination of aminophylline (Phyllocontin Continus tablets) and salbutamol in the management of chronic obstructive airways disease. Br J Clin Pharmocol 1980; 9: 359-364.
7. Guyatt GH, Townsend M, Pugsley SO, et al. Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis 1987; 135: 1069-1074.
8. Thomas P, Pugsley JA, Stewart JH. Theophylline and salbutamol improve pulmonary function in patients with irreversible chronic obstructive pulmonary disease. Chest 1992; 101: 160-165.
9. Dullinger D, Kronenberg R, Niewoehner DE. Efficacy of inhaled metaproterenol and orally-administered theophylline in patients with chronic airflow obstruction. Chest 1986; 89: 171-173.
10. Lam A, Newhouse MT. Management of asthma and chronic airflow limitation. Are methylxanthines obsolete? Chest 1990; 98: 44-52.
11. Shannon M, Lovejoy Jr. FH. The influence of age vs peak serum concentration on life- threatening events after chronic theophylline intoxication. Arch Intern Med 1990: 150: 2045-2048.
12. Koyama H, Nishimura K, Ikeda A, et al. A comparison of the bronchodilating effects of oxitropium bromide and fenoterol in patients with chronic obstructive pulmonary disease. Chest 1993; 104: 1743-1747.
13. Bleecker ER, Britt EJ. Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease. Am J Med 1991; 91: 24S-27S.
14. Van Andel Ae, Resiner C, Menjohe SS, Witek TJ. Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987 to 1995. Chest 1999; 115: 703-707.
15. Rudolf M. The reality of drug use in COPD. The European perspective. Chest 2000; 117. 29S-32S.
16. Combivent Inhalation Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. Chest 1994; 105: 1411-1419.
17. Karpel JP, Kotch A, Zinny M, Pesin J, Alleyne W. A comparison of inhaled ipratropium, oral theophylline plus inhaled beata-agonist, and the combination of all three in patients with COPD. Chest 1994; 105: 1089-1094.
18. Ramsdell JW, Henderson S, Renvall MJ, Salmon DP, Ferguson P. Effects of theophylline and ipratropium on cognition in elderly patients with chronic obstructive pulmonary disease. Allergy Asthma Immunol 1996; 76: 335-340.
19. Tsukino M, Nishimura K, Ikeda A, Hajiro T, Koyama H, Izumi T. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Thorax 1998; 53: 269-273.
20. Peel ET, Anderson G. A dose response study of oxitropium bromide in chronic bronchitis. Thorax 1984; 39: 453-456.
21. Ikeda A, Nishimura K, Koyama H, et al. Comparative close-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax 1995; 5O: 62-66.
22. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-1327.
23. Hay JG, Stone P, Carter J, Church S, Eyre-Brook A, Pearson MG, Woodcock AA, Calverley PMA. Bronchodilator reversibility, exercise performance and breathelssness in stable chronic obstructive pulmonary disease. Eur Respir J 1992; 5: 659-664.
24. Belman MJ, Warren C, Botnick, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 967-975.
25. O'Donnell D, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1557-1565.
26. Mahler DA, Matthay RA, Snyder PE, et al. Sustained-release theophylline reduces dyspnoea in nonreversible obstructive airway disease. Am Rev Respir Dis 1985; 131: 22-25.
27. Taylor DR, Buick B, Kinney C, et al. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis 1985; 131: 747-751.
28. Tandon MK, Kailis SG. Bronchodilator treatment for partially reversible chronic obstructive airways disease. Thorax 1991; 46: 248-251.
29. Tsukino M, Nishimura K, Ikeda A, et al. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Thorax 1998; 53: 269-273.
30. Pellegrino R, Rodarte JR, Brusasco V. Assessing the reversibility of airway obstruction. Chest 1998; 114: 1607-1612.
31. Tantucci C, Duguet A, Similowski T, et al. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J 1998; 12: 799-804.
32. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 542-549.
33. Murciano D, Auclair MH, Pariente R, et al. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989; 320: 1521 -1525.
34. Oga T, Nishimura K, Tsukino M, et al. The effects of oxitropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. A comparison of three different exercise tests. Am J Respir Crit Care Med 2000; 161: 1897-1901.
35. Giorgi-Conciato M, Daniotti S, Ferrari PA, et al. Efficacy and safety of pirenzepine in peptic ulcer and in non ulcerous gastroduodenal diseases. A multicentre controlled clinical trial. Scand J Gastroenterol Suppl 1982; 81: 1-41.